Moderate-intensity intermittent walking
Moderate-intensity intermittent walking has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 24, 2026: “Moderate-Intensity Intermittent Walking Improves Liver-Related Biomarkers and Reduces Inflammation in Postmenopausal Women With Obesity: A Randomized Controlled Study”.
1 paper studies it4 findingsUpdated
See all 1 papers on moderate-intensity intermittent walking
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Significant improvements were observed in the TG group in liver enzymes alanine-transaminase (ALT), (p = 0.002, d = 0.29)”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave moderate-intensity intermittent walking to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases alanine transaminasep = 0.002, d = 0.29 down: Decreases C-reactive proteinp = 0.007, d = 0.49 down: Decreases body massp < 0.001 | Randomized trial10-week | 36 peopleWomenmean age 55.7 ± 3.5 yearsPostmenopausal women; sedentary postmenopausal women with obesity | European journal of sport science, Feb 24, 2026 |
What did studies of moderate-intensity intermittent walking find?
4Studies of moderate-intensity intermittent walking measured 4 outcomes, among them aerobic capacity, body mass and C-reactive protein.
Aerobic capacity
upin humans1
1 study
Aerobic capacity
upin humans1
Moderate-intensity intermittent walking improves aerobic capacity in humans (sedentary postmenopausal women with obesity) (p = 0.031).
“along with increased aerobic capacity (p = 0.031).”
Human trialsedentary postmenopausal women with obesityMIWT protocol (4 sessions/week, ~85 min/session)10-weekfemalesn = 36
European journal of sport science
Body mass
downin humans1
1 study
Body mass
downin humans1
Moderate-intensity intermittent walking decreases body mass in humans (sedentary postmenopausal women with obesity) (p < 0.001).
“Additionally, significant reductions were found in body mass (p < 0.001), BMI (p < 0.001), body fat (p = 0.001), and waist circumference (p < 0.001)”
Human trialsedentary postmenopausal women with obesityMIWT protocol (4 sessions/week, ~85 min/session)10-weekfemalesn = 36
European journal of sport science
C-reactive protein
downin humans1
1 study
C-reactive protein
downin humans1
Moderate-intensity intermittent walking decreases C-reactive protein in humans (sedentary postmenopausal women with obesity) (p = 0.007, d = 0.49).
“C-reactive-protein (CRP) (p = 0.007, d = 0.49).”
Human trialsedentary postmenopausal women with obesityMIWT protocol (4 sessions/week, ~85 min/session)10-weekfemalesn = 36
European journal of sport science
Alanine transaminase
downin humans1
1 study
Alanine transaminase
downin humans1
Moderate-intensity intermittent walking decreases alanine transaminase in humans (sedentary postmenopausal women with obesity) (p = 0.002, d = 0.29).
“Significant improvements were observed in the TG group in liver enzymes alanine-transaminase (ALT), (p = 0.002, d = 0.29)”
Human trialsedentary postmenopausal women with obesityMIWT protocol (4 sessions/week, ~85 min/session)10-weekfemalesn = 36
European journal of sport science